1 
                                     CAPRI Adaptive protocol  Ver 3.0  7/26/2020  
   
 
 
 
A randomized controlled adaptive study comparing COVID -19 convalescent plasma to non-immune 
plasma  to limit coronavirus -associated complications in hospitalized patients.  
 
  
 
IND #  21774  
 
 
 
  
 
Protocol Chairs:  Annie Luetkemeyer & Priscilla Hsue  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Version 3.0 
7/26/2020
2 
                                     CAPRI Adaptive protocol  Ver 3.0  7/26/2020  
  
 
 
 
A randomized , controlled , adaptive study comparing COVID -19 convalescent plasma to non-immune 
plasma  to limit coronavirus -associated complications in hospitalized patients.  
 
SIGNATURE PAGE  
 
I will conduct the study in accordance with the provisions of this protocol and all applicable protocol -related 
documents. I agree to conduct this study in compliance with United States (US) Health and Human Service 
regulations (45 CFR 46); applicable U.S.  Food and Drug Administration regulations; standards of the 
International Conference on Harmonization Guideline for Good Clinical Practice (E6); Institutional Review 
Board/Ethics Committee determinations; all applicable in -country, state, and local laws an d regulations; and 
other applicable requirements and institutional policies.  
 
 
 
Principal Investigator: _______________________________________________  
Print/Type  
 
 
  
 
Signed: ___________________________________           Date: _____________  
Name/Title  
  
3 
                                     CAPRI Adaptive protocol  Ver 3.0  7/26/2020  
  
Contents  
1 PROTOCOL TEAM ROSTER  ................................ ................................ ................................ ................................ ...............  5 
2 LIST OF ABBREVIATIONS  ................................ ................................ ................................ ................................ .................  6 
3 PROTOCOL  SUMMARY  ................................ ................................ ................................ ................................ ....................  8 
4 RATIONALE/BACKGROUND:  ................................ ................................ ................................ ................................ ..........  12 
4.1 Background and scientific rationale  ................................ ................................ ................................ ......................  12 
 Experience with the use of convalescent plasma against coronavirus diseases  ................................ ..........  13 
 Known potential risks  ................................ ................................ ................................ ................................ .... 14 
 Known potential benefits  ................................ ................................ ................................ ..............................  15 
 Target population  ................................ ................................ ................................ ................................ ..........  15 
 Antibody evaluation of CCP units ................................ ................................ ................................ ..................  17 
 Viral load testing  ................................ ................................ ................................ ................................ ...........  17 
 Adaptive trial design  ................................ ................................ ................................ ................................ ..... 17 
 Collaboration with longitudinal cohorts and data pooling efforts  ................................ ...............................  18 
 Future direction  ................................ ................................ ................................ ................................ ............  18 
5 INVESTIGATIONAL PLAN:  ................................ ................................ ................................ ................................ ..............  19 
5.1 Study objectives  ................................ ................................ ................................ ................................ ....................  19 
5.2 Study Definitions  ................................ ................................ ................................ ................................ ...................  22 
5.3 Study Population  ................................ ................................ ................................ ................................ ...................  22 
 Inclusion Criteria for Enrollment:  ................................ ................................ ................................ ..................  22 
 Exclusion Criteria  ................................ ................................ ................................ ................................ ...........  22 
 Subject Withdrawal  ................................ ................................ ................................ ................................ .......  22 
 Treatment  ................................ ................................ ................................ ................................ .....................  23 
 Randomization:  ................................ ................................ ................................ ................................ .............  23 
 Study drug administration  ................................ ................................ ................................ ............................  23 
 Concomitant medications  ................................ ................................ ................................ .............................  24 
 Prohibited medications  ................................ ................................ ................................ ................................ . 24 
5.4 Study procedures  ................................ ................................ ................................ ................................ ..................  25 
6 STATISTICA L PLAN  ................................ ................................ ................................ ................................ .........................  31 
6.1 Sample Size and Power Considerations  ................................ ................................ ................................ ................  31 
6.2 Statistical Analysis  ................................ ................................ ................................ ................................ .................  32 
 Primary endpoint  ................................ ................................ ................................ ................................ ..........  32 
 Secondary endpoint (clinical status):  ................................ ................................ ................................ ............  33 
 Other secondary endpoints:  ................................ ................................ ................................ .........................  33 
 Analysis of AE data  ................................ ................................ ................................ ................................ ........  33 
4 
                                     CAPRI Adaptive protocol  Ver 3.0  7/26/2020  
 
 Analysis of the anti -SARS -CoV-2 levels and inflammatory markers.  ................................ ............................  33 
 Analysis the rates, levels and duration of SARS -CoV-2 RNA in NP/MTN swabs  ................................ ...........  34 
 Analysis of ICU rate, in -hospital mortality and 29 day mortality  ................................ ................................ .. 34 
6.3 Adaptive trial design  ................................ ................................ ................................ ................................ .............  34 
7 HUMAN SUBJECTS PROTECTIONS  ................................ ................................ ................................ ................................ . 35 
7.1 Risks and Benefits  ................................ ................................ ................................ ................................ .................  35 
 Potential risks  ................................ ................................ ................................ ................................ ................  35 
 Safety measures  ................................ ................................ ................................ ................................ ............  35 
7.2 Definitions  ................................ ................................ ................................ ................................ .............................  35 
7.3 Safety Reporting  Requirements  ................................ ................................ ................................ ............................  36 
 Reporting Interval  ................................ ................................ ................................ ................................ .........  36 
 Investigator’s Assessment of Adverse Events  ................................ ................................ ...............................  36 
 Assessment of Seriousness  ................................ ................................ ................................ ...........................  36 
 Assessment of Association  ................................ ................................ ................................ ............................  37 
7.4 Safety Oversight  ................................ ................................ ................................ ................................ ....................  37 
 Monitoring Plan  ................................ ................................ ................................ ................................ ............  37 
7.5 Study compliance with clinical trial requirements  ................................ ................................ ................................  37 
8 STUDY MODIFICATION  ................................ ................................ ................................ ................................ ..................  38 
8.1 Halting Criteria for the Study  ................................ ................................ ................................ ................................  38 
8.2 Halting Criteria/Rules for Subject Infusion:  ................................ ................................ ................................ ..........  38 
Infusion of study drug will be halted if any of the following manifestations of anaphylaxis develop and will not be 
restarted:  ................................ ................................ ................................ ................................ ................................ ..........  38 
9 ETHICS/PROTECTION OF HUMAN SUBJECTS  ................................ ................................ ................................ ................  39 
9.1 Ethical Standard  ................................ ................................ ................................ ................................ ....................  39 
9.2 Institutional Review Board  ................................ ................................ ................................ ................................ .... 39 
9.3 Informed Consent Process  ................................ ................................ ................................ ................................ .... 39 
9.4 Subject Confidentiality  ................................ ................................ ................................ ................................ ..........  39 
9.5 Future Use of Stored Specimens  ................................ ................................ ................................ ...........................  40 
9.6 Data management and monitoring ................................ ................................ ................................ .......................  40 
 Source Documents  ................................ ................................ ................................ ................................ ........  40 
 Data Management Plan  ................................ ................................ ................................ ................................  40 
 Data Capture Methods  ................................ ................................ ................................ ................................ .. 41 
 Study Record Retention  ................................ ................................ ................................ ................................  41 
 
  
5 
                                     CAPRI Adaptive protocol  Ver 3.0  7/26/2020  
 1 PROTOCOL TEAM ROSTER  
Protocol Chairs  
Annie Luetkemeyer  
Division of HIV, Infectious Diseases and Global Medicine  
Zuckerberg San Francisco General Hospital  
University of California, San Francisco  
Box 0874  
995 Potrero Ave  
San Francisco, CA 94110  
Phone 415 476 4082 ext 130  
Fax 415 476 6953  
annie.luetkemeyer@ucsf.edu  
 
Priscilla Hsue  
Division of Cardiology  
1001 Potrero Ave, 5G202  
San Francisco, CA 94110  
(628)  206-8257  
Fax (628) 206-5447  
Priscilla.hsue@ucsf.edu  
 
Statistician  
David Glidden  
 
Investigators  
Peter Chin Hong  
Pierre Cedric -Crouch  
Sarah Doernberg  
Jonathan Esensten  
Monica Fung  
Brian Graham  
Carolyn Hendrickson  
Tim Henrich  
Hannah Jang  
Jennifer Ling  
Sulggi Lee  
Ashok Nambiar  
Phillip Norris  
  
6 
                                     CAPRI Adaptive protocol  Ver 3.0  7/26/2020  
 2 LIST OF ABBREVIATION S 
ADR: Adverse Drug Reaction  
ADE: A ntibody -mediated enhancement of infection  
AE: Adverse Event/Adverse Experience  
APACHE: Acute Physiological Measurement and Chronic Health Evaluation  
CBC: Complete Blood Count  
CCP: COVID -19 Convalescent Plasm  
CDC: United States Centers for Disease Control and Prevention  
CFR: Code of Federal Regulations  
CLIA: Clinical Laboratory Improvement Amendment of 1988  
COI: Conflict of Interest  
COVID -19: Coronavirus Disease  
CRF: Case Repo rt Form  
CRP: C -Reactive Protein  
DMC: Data Management Center  
DSMB: Data and Safety Monitoring Board  
EUA: Emergency Use Authorization  
FDA: Food and Drug Administration  
GCP: Good Clinical Practice  
HBV: Hepatitis B virus  
HCV: Hepatitis C virus  
HFNC: High flow nasal cannula  
HIV: Human immunodeficiency virus  
HTLV: Human T -cell lymphotropic virus  
IB: Investigator’s Brochure  
ICF: Informed Consent (Informed Consent Form)  
ICH: International Conference on Harmonization  
ICU: Intensive Care Unit  
IEC: Independent Ethics Committee  
IND: Investigational New Drug Application  
IRB: Institutional Review Board 
ISBT: International Society of Blood Transfusion  
ISM: Independent Safety Monitor  
IWRS:  Interactive Web Response System  
LOS: Length of Stay  
MERS: Middle East Respiratory Syndrome  
mNGS: Metagenomic Next generation sequencing  
MTN: Mid -turbinate nalal  
NP: Nasopharyngeal  
OHRP:  Office of Human Research Protections  
OP: Oropharyngeal  
RT-PCR: Reverse Transcriptase Real -Time Polymerase Chain Reaction  
PK: Pharmacokinetic  
RDV: Remdesivir  
SAE: Serious Adverse Event 
SARS: Severe Acute Respiratory Syndrome  
SARS -CoV-2: Severe Acute Respiratory Syndrome Coronavirus 2  
SOFA:  Sequential Organ Failure Assessment  
TACO: Transfusion -associated Circulatory Overload  
T. cruzi: Trypanosoma cruzi  
TRALI: Transfusion -related Acute Lung Injury  
UP: Unanticipated Problem  
7 
                                     CAPRI Adaptive protocol  Ver 3.0  7/26/2020  
 UPnonAE: Unanticipated Problem that is not an Adverse Event  
  
8 
                                     CAPRI Adaptive protocol  Ver 3.0  7/26/2020  
 3 PROTOCOL SUM MARY  
 
Long title:   A randomized controlled adaptive study comparing COVID -19 convalescent plasma  (CCP) 
to non-immune plasma  to limit coronavirus -associated complications in hospitalized patients.  
 
Sample Size:   n=50 
 
Study Population:  Hospitalized COVID -19 patients aged ≥18 years with respiratory symptoms  and hypoxia, 
who do not  currently  require mechanical ventilation , enrolled  within 3 da ys of admission to the hospital OR 
within 14 days of initial onset of symptoms.  
 
Study Duration:   May 25,  2020 to April 30, 2021  
 
Study Design : This randomized , pragmatically blinded, placebo -controlled, adaptive  trial will assess the 
efficacy and safety of anti -SARS -CoV-2 convalescent plasma in hospitalized patients with acute respiratory 
symptoms up to 14 days after the onset of initial symptoms . 
 
A total of 50 eligible subjects will be randomized in a 1:1 ratio to receive either convalescent fresh frozen 
plasma from blood donors who have recovered from COVID -19 containing antibodies to SARS -CoV-2 or 
control (standard fresh frozen plasma collected prior to 12/ 1/2019 or with documented negative SARS -CoV-2 
antibody). Should additional anti -COVID agents (anti -viral and/or anti -inflammatory) become available for use 
as standard of care during implementation, the sample size will be recalculated and increased to accoun t for 
the estimated impact that these agents may have on the reducing the progression to the primary endpoint of 
severe hypoxemia.  
 
Clinical, Laboratory and Imaging Data  
1. Date of symptom onset and history of presenting illness  
2. Demographics: A ge, sex, comorbidities , zip code  + 4  
3. Vital Signs: Temperature, respiratory rate, blood pressure, oxygen saturation , oxygen requirements , 
APACHE score, SOFA score .  
4. Laboratory Data :  
 
 Hematologic Markers: CBC  with differential  (neutrophil, lymphocyte count s explicitly recorded), 
PT/PTT, D -dimer   
 Metabolic Markers: Creatinine , liver function tests  
 Inflammatory Markers:  CRP , ferritin  
 Arterial blood gas values, if available  
 Measurement of isotype,  total antibody , and neutralizing capacity of donor pla sma antibodies  to 
SARS -CoV-2 
 Serum or plasma antibody  to SARS -CoV-2: Day 1, 5,8,15, 29, 120  
 SARS -CoV-2 PCR from nasopharyngeal swab  (NP) or mid -turbinate  nasal  swab  (MTN  Day 
1,2,5,8,15  
 
5. Chest imaging (CT or Chest x -ray): obtained as part of standard care   
 
Primary Objective:  Evaluate the efficacy of convalescent fresh frozen plasma from blood donors who 
have recovered from Covid -19 containing antibodies to SARS -CoV-2 versus control (standard fresh frozen 
plasma ) to prevent severe hypoxemia  during the 14 days after administration in hospitalized patients with 
COVID -19 who are within 72 hours  of hospital admission OR 14 days of symptom onset.  
Primary Endpoint : Progression to mechanical ventilation/ECMO  for hypoxia/hypercarbia , or death from 
any cause  
9 
                                     CAPRI Adaptive protocol  Ver 3.0  7/26/2020  
  
Safety and Efficacy of the intervention will be assessed during multiple time  points Day 1 (baseline), 
2,5,8,15, 29 and once at month 4 (day 120) . 
 
 
 
OBJECTIVES  ENDPOINTS (OUTCOME MEASURES)  
Primary  Objective   
Evaluate the efficacy of convalescent fresh 
frozen plasma from blood donors who have 
recovered from Covid -19 containing antibodies 
to SARS -CoV-2 versus control (standard fresh 
frozen plasma) to prevent mechanical intubation 
or death  within 14 days of CPP administration in 
hospitalized patients  with COVID -19 who are 
within 3 days of hospital admission or 14 days of 
symptom onset.  
. Progression to mechanical ventilation or death  within the 
first 14 days of enrollment. . A secondary endpoint will 
evaluate progression to endpoint within the first 28 days of 
enrollment.   
    
Key Secondary  Objectives   
To evaluate the clinical efficacy of CCP  relative 
to the control arm in adults hospitalized with 
COVID -19 according to clinical status (8 -point 
ordinal scale) at Day 29 
 
 
 
 
 
  Death;  
 Hospitalized, on invasive mechanical ventilation or 
ECMO;  
 Hospitalized, on non -invasive ventilation or high flow 
oxygen devices;  
 Hospitalized, requiring supplemental oxygen;  
 Hospitalized, not requiring supplemental oxygen - 
requiring ongoing medical care (COVID -19 related or 
otherwise);  
 Hospitalized, not requiring supplemental  oxygen - no 
longer requires ongoing medical care;  
 Not hospitalized, limitation on activities and/or requiring 
home oxygen;  
 Not hospitalized, no limitations on activities.  
 
10 
                                     CAPRI Adaptive protocol  Ver 3.0  7/26/2020  
 OBJECTIVES  ENDPOINTS (OUTCOME MEASURES)  
Additional Secondary Objectives   
 
To evaluate the clinical efficacy of different 
investigational therapeutics as compared to the 
control arm as assessed by:  
Clinical Severity  Ordinal scale : 
 Time to an improvement of one category 
and two categories from Day 0 (baseline) 
using an ordinal scale.  
 Subject clinical status using ordinal scale at 
Days 2,5,8,15, 29   
 Mean change in the ordinal scale from Day 
1 to Days 2,5,8,15, 29     
 
 
 Clinical outcome assessed using ordinal scale daily 
while hospitalized and on Days 15, 29 and 120  
 Time to clinical recovery ( defined as ordinal score 1 -
3)  
 
 
 
National Early Warning Score (NEWS):  
 Time to discharge or to a NEWS of ≤ 2 
and maintained for 24 hours,  whichever 
occurs first.  
 Change from Day 1 to Days 2,5,8,15, 29     
 NEWS assessed daily while hospitalized  
Oxygenation:  
 Oxygenation use up to Day 120. 
 Incidence and duration of new oxygen use 
during the study.  
 Oxygen requirement on day 1,2,5,8,15, 29     
 Days of supplemental oxygen (if applicable) up to 
Day 29 
 PaO2/FiO2 ratio or SpO2/FiO2  
 O2 requirement at day 120 
 
Non-invasive ventilation/high flow oxygen:  
 Non-invasive ventilation/high flow oxygen 
use up to Day 29. 
 Incidence and duration of new non -
invasive ventilation or high flow oxygen 
use during the study.   Days of non -invasive ventilation/high flow oxygen (if 
applicable) up to Day 29 
Invasive Mechanical Ventilation / 
extracorporeal membrane oxygenation 
(ECMO):  
 Ventilator / ECMO use up to Day 29. 
 Incidence and duration of new mechanical 
ventilation or ECMO use during the study.   
 Days of invasive mechanical ventilation/ECMO (if 
applicable) up to Day 29. 
Hospitalization  
 Duration of hospitalization (days).  
  
 Days of hospitalization as of  Day 29 and day 120 
Mortality  
 15-day mortality  
 29-day mortality  
 120-day mortality  
  
 Date and cause of death (if applicable)  
 
To evaluate the safety of CCP as compared 
to the control arm as assessed by:   
 SAEs  
11 
                                     CAPRI Adaptive protocol  Ver 3.0  7/26/2020  
  Cumulative incidence of SAEs  through 
Day 29. 
 Cumulative incidence of Grade 3 and 4 
clinical and/or laboratory AEs through Day 
29. 
 Transfusion associated adverse events  
  Grade 3 and 4 AEs  
 Grade 2 or higher AE’s attributed to CCP 
 
 Exploratory Objectives   
To evaluate the virologic efficacy of CCP 
as compared to the control arm as 
assessed by:  
 Percent of subjects with SARS -CoV-2 
detectable in nasal  sample at Days 
1,5,8,15  
 Quantitative SARS -CoV-2 virus in 
NP/MTN   sample at Days 1,2,5,8,15  
  
 Qualitative and quantitative polymerase chain 
reaction (PCR) for SARS -CoV-2 in NP/MTN  swab on 
Day 1,2,5,8,15  (while hospitalized)  
 
 
Study population  
 Inclusion Criteria for Enrollment : 
1. Patients ≥18 years of age  
2. Hospitalized with COVID -19  
3. Enrolled within 72 hours of hospitalization OR within day 14 from first symptoms  of illness  
4. Pulmonary infiltrates on chest imaging  
5. Oxygenation of <95% on room air  
6. Laboratory confirmed COVID -19  
 
Exclusion Criteria  
1. Contraindication to transfusion due to inability to tolerate additional fluid, such as due to 
decompensated congestive heart failure  
2. Baseline requirement for oxygen supplementation prior to COVID -19 infection or use of positive 
pressure therapy for sleep disordered breathing  
3. Currently experiencing severe hypoxemic failure, as defined in study endpoints  
4. Prior receipt of plasma products , IVIG, or hyperimmune globulin within past 3 months  
5. Not currently enrolled another interventional clinical trial of COVID -19 treatment .  
 
Note: If taking medications with potential anti -COVID activity  for the purpose of COVID -19 treatment  
that do not yet have data to support efficacy, such as IL-6 antagonists   these medications must be 
stopped prior to enrollment. Rece ipt of current standard of care COVID -19 treatment , including 
remdesivir  and dexmethasone  is permitted and should be recorded as concomitant m edications.  
 
 
  
12 
                                     CAPRI Adaptive protocol  Ver 3.0  7/26/2020  
 4 RATIONALE/BACKGROUND : 
4.1 Background and scientific  rationale  
Human convalescent plasma is a treatment option for COVID -19 and could be rapidly available when 
there are enough  people who have recovered and donate  plasma containing  high titer  (anti- SARS -CoV-
2) neutralizing immunoglobulin s. As more individuals contract COVID -19 and recover, the number of 
potential donors will continue to increase, to allow greater use.  
 
Use of convalescent plasma is a form of passive antibody therapy that involves the administration of 
antibodies to a given agent to a susceptible individual for the purpose of pre venting or treating the 
infectious disease it causes. In contrast, active vaccination requires the induction of an immune response 
that takes time to develop and varies in efficacy depending on the vaccine recipient. Some 
immunocompromised patients fail to  achieve an adequate immune response to active vaccination and at 
present, there are no vaccines to prevent COVID -19. When given to a susceptible person, antibody used 
for therapy will circulate in the blood, reach tissues and hopefully mediate a beneficia l effect by anti -
microbial  and anti-inflammatory activity [2]. Depending on antibody amount and composition, protection 
conferred by transferred immunoglobulin can last from weeks to months.  
 
Passive  antibody administration is the only means of providing immediate immunity to susceptible persons 
and immunity of any measurable kind for susceptible, including immunocompromised patients  with Covid -
19. This kind of antibody therapy  has a storied history g oing back to the 1890s and was the only means 
of treating certain infectious diseases prior to the development of antimicrobial therapy in the 1940s [3, 4] . 
Experience from prior outbreaks with other coronaviruses, such as SARS -CoV-1 shows that such 
convalescent plasma contains neutralizing antibodies to the relevant virus  [5]. In the case of SARS -CoV-
2, the anticipated mechanism of action by which passive antibody therapy would mediate protection is 
viral neutralization. However, other mechanisms may be possible, such as antibody dependent cellular 
cytotoxicity and/or phagocyt osis. Convalescent serum was also used in the 2013 African Ebola epidemic. 
A small non -randomized study in Sierra Leone revealed a significant increase in survival for those treated 
with convalescent whole blood relative to those who received standard trea tment  [6].  
 
When used for therapy, antibody is most effective when administered shortly after the onset of symptoms. 
The reason for temporal variation in efficacy is not well understood but could reflect that passive antibody 
works by neutralizing the initial inoculum, which is likely to be much smaller than that of estab lished 
disease. Another explanation is that antibody works by modifying the inflammatory response, which is 
also easier during the initial immune response, which may be asymptomatic  [7]. For example , passive 
antibody therapy for pneumococcal pneumonia was most effective when administered shortly after the 
onset of symptom s and there was no benefit if antibody administration was delayed past the third day of 
disease  [3]. Clinical outcomes after convalescent antibody therapy were better when it was administered 
to ill patients SARS -CoV-1 within 14 days after onset of symptoms (discussed below) [8].  Our goal is to 
treat patients who are sick enough to warrant hospitalization but do not have severe respiratory disease 
and/or ARDS.    
 
13 
                                     CAPRI Adaptive protocol  Ver 3.0  7/26/2020  
 
 Experience with the use of convalescent plasma against coronavirus diseases  
In the 21st century, there were two other epidemics with coronaviruses that were associated with high 
mortality, SARS1 i n 2003 and MERS in 2012. In both outbreaks, the high mortality and absence of 
effective therapies led to the use of convalescent plasma. The largest study involved the treatment of 80 
patients in Hong Kong with SARS  [8]. Consistent with historical data that earl ier administration of antibody 
is more likely to be effective, 30 patients treated a mean of 11.7 (+/ - 2.3) days after symptom onset had 
improved prognosis defined by discharge from hospital before day 22 , whereas 47 patients who received 
plasma a mean of 16 days after symptom onset died before day 22 or had a late discharge.  The mortality 
rates in the two groups were 6.3% and 21.9%, respectively ( P=0.08) , and those who were nasal swab 
PCR positive and seronegative for coronavirus at the time of therapy had improved prognosis. There is 
also some anecdotal information on the use of convalescent plasma in seriously ill individuals. Three 
patients with SARS 1 in Taiwan were treated with 500 ml of convalescent plasma, resulting in a reduction 
in plasma virus titer and each survived [9]. Three patients with MERS in South Korea were treated with 
convalescent plasma, but only two of the recipients developed neutralizing antibody  one week after  
infusion  [10].  The latter study highlights a challenge in using convalescent plasma ; some who recover 
may not have high titers of neutralizing antibody  [11]. In addition, only 2 of 4 donor plasma infusions 
showed neutralizing an tibody activity.  This is consistent with a n analysis of 99 samples of convalescent 
sera from patients with MERS which showed that 87 had neutralizing antibody with a geometric mean titer 
of 1:6 4. This suggests that antibody declines with time and/or only a few  patients make high titer 
responses. Our study addresses this issue by screening plasma for antibody to SARS -CoV-2 and will only 
use plasma with SARS -CoV-2 antibodies  detected. However, it is possible non -neutralizing antibodies 
may also  contribute to  protection as described for other viral diseases  [12, 13] .  In addition, to ensure that 
the control arm plasma does not have SARS -CoV-2 antibodies present, control fresh frozen plasma will 
be used from prior to December,2019 or testing for SARS -CoV-2 antibodies  in the control plasma will be 
performed  immediately prior to administration.  
A recently performed pilot study in Wuhan , China  collected convalescent liquid plasma from COVID -19 
positive patients 3 weeks following the onset of illness and 4 days post -discharge  and treated patients 
diagnosed with ‘severe COVID -19’ as defined by WHO Interim Guidance and the Guideline of Diagnosis 
and Treatment of COVID -19 National Health Commission of China  [14]. Ten patients were treated with 
one dose of convalescent plasma (200ml, >1:640 titer by neutralization assay) at a median of 16.5 days 
(11-19.3 days) post -onset of symptoms. A COVID -19 positive control cohort was retrospectively identified 
and matched by demographics, comorbidities, and severity of illness. There were no serious adverse 
reactions or safety events recorded  with convalescent plasma , including no reported transfusion related 
reaction s, transfusion -related acute lung injury, or antibody -mediated enhancement of infection. In the 
treatment group, there were 0 deaths, 3 discharges and 7 patients improved , whereas there were 3 deaths 
and 7 patients who improved  in the control group (p < 0.001).  In addition, 2 of 3 patients in the tre atment 
on mechanical ventilation were weaned to high flow nasal can nula, which was discontinued in one patient. 
There was a reduction in blood RNA viral load  in 7 of 10 patients  on day 6 post -convalescent plasma  
therapy as well as  improvement in laboratory  markers. There were also varying degrees of improvement 
in pulmonary lesions on chest CT after convalescent plasma therapy . In another case series from China, 
five severely ill patients with COVID -19, all on mechanical ventilation  received  convalescent plasma within 
22 days of admission [15]. Temperature s normalized in 4 of 5 patients within 3 day s, SOFA scor es 
decreased, and there was improvement in oxygenation  and ARDS resolution. All survived, with 3 
discharged home and 2 in stable condition. These reports suggest convalescent plasma may hold promise 
for ameliorating the severity of Covid -19 and  deserves immediate investigation for this indication.  
14 
                                     CAPRI Adaptive protocol  Ver 3.0  7/26/2020  
  
 Known potential risks  
A theoretical risk of administration of convalescent plasma is the phenomenon of antibody -mediated 
enhancement of infection (ADE). ADE can occur in viral diseases , such as dengue  and involves an 
enhancement of disease in the presence of certain antibodies. For coronaviruses, several mechanisms of 
ADE have been described , including the theoretical concern that antibodies to one type of coronavirus 
could enhance infection to a nother strain  [16]. It may be possible to predict the risk of ADE in SARS -CoV-
2 experimentally, as proposed for MERS  [16]. Since the proposed use of convalescent plasma in the 
COVID -19 epidemic  would rely on preparations with high titers of antibody against the same virus, SARS2 -
CoV-2, ADE may be unlikely. Available evidence from the use of convalescent plasma in patients with 
SARS1 and MERS  [17] demonstrated it is safe and there were no adverse effects in a pilot study of  
patients with COVID -19 [14]. Nevertheless, caution and vigilance will be exercised to use clinical and 
laboratory measures to detect  evidence of enhanced infection.  
Another theoretical risk is that CCP  to those exposed to SARS -CoV-2 may prevent disease but mo dify 
the immune response such that those who are treated may mount  attenuated immune response s. This 
may leave them vulnerable to subsequent re -infection. Passive  antibody administration before vaccination 
with respiratory syncytial virus attenuated  humora l but not cellular immunity  [18]. This will be investigated 
as part of this clinical trial by comparing immune responses in those who receive standard plasma and 
conval escent plasma. If responses differ, those with attenuated levels could be vaccinated against 
COVID -19 when a vaccine becomes available. Nonetheless, these concerns are modest compared to the 
possible benefit of reducing the risk of respiratory failure and avoiding mechanical ventilation . 
Finally, there are risks associated with any transfusion of plasma including transmission of transfusion 
transmitted viruses (e.g. HIV, HBV, HCV, etc.), allergic transfusion reactions, anaphylaxis to transfusion, 
febrile tr ansfusion reaction, transfusion related acute lung injury (TRALI), transfusion associated cardiac 
overload (TACO), and hemolysis should ABO incompatible plasma be mistakenly administered. To 
minimize the risks of disease transmission, all plasma donors wil l be required to meet full allogeneic blood 
donation requirements as determined  by FDA  and the collection center . Donors are screened  for 
behavioral risk factors for bloodborne infections  using the standard blood donor history questionnaire 
(DHQ)  and exten sive testing for blood borne pathogens  using FDA -licensed tests for blood product testing . 
In addition, donors will fulfill all FDA convalescent donor requirements which require a history of COVID19 
illness  (documented by positive COVID -19 test at time of illness OR positive COVID -19 serology) and 
complete resolution of symptoms at least 28 days prior to donation, or complete resolution of symptoms  
at least  14 days prior to donation with negative COVID -19 na sopharyngeal swab or molecular diagnostic 
test from blood [19].  
A recent observational series described the safety of CCP administered t o over 5000 hospitalized patients 
with COVID -19 infection. The incidence of adverse events in the day after plasma infusion was < 1% with 
only 2 of 36 events attributed to CCP by the treating clinician , suggesting a favorable initial safety signal 
and no c lear evidence of ADE. [20]  
15 
                                     CAPRI Adaptive protocol  Ver 3.0  7/26/2020  
 
 Known potential benefits  
The most important  potential benefit is that convalescent plasma may reduce progression to respiratory 
failure in patients with COVID -19 and early respiratory symptoms, such as shortness of breath, cough, 
chest pain , and pulmonary infiltrates . The benefit of plasma is expected to  be an improvement in 
symptoms , oxygenation , the need for mechanical ventilation  and possibly  reduced  mortality. Base d on 
historical experience with antibody administration, antibody administration  is expected to be effective  
relatively early in disease  [2]. Convalescent plasma was safe, reduced symptoms , and improved 
oxygenation in a non -randomized open label study of patients with more advanced disease in Wuhan, 
China  [14].  
Given  historical data showing convalescent plasma was safe and possibly effective in patients with SARS1 
[8, 17] , and emerging data from China suggest it is safe and possibly effective in patients with severe 
COVID -19, the benefits of its use in those at high risk for severe disease  outweigh the risks. However, for 
all patients in whom  convalescent plasma administration is considered, a risk -benefit assessment will be 
conducted to assess individual variables.  This protoc ol proposes a randomized controlled pragmatically 
blinded  trial to assess the efficacy of convalescent plasma in preventing severe hypoxemia  in patients 
with C OVID -19. A JAMA editorial by experts note the importance of  randomized clinical trials to 
demonst rate efficacy  of this approach  and change the course of the epidemic  [21]. 
 Target population  
This study will enroll hypoxic hospitalized COVID -19 patients, a group that is at elevated risk for poor 
outcomes and prog ressive respiratory failure. To date, approximately 30-50% of hospitalized San 
Francisco COVID -19 patients have require d intensive care level treatment, the majority due to respiratory 
failure [1]. This high progression to ICU level care due to respiratory failure has been seen across the US . 
This study targets patients who are st ill early in the course of disease, when CCP may be most effective, 
the “green zone” described in Figure 2.  Once severe respiratory decompensation and ARDS occur and 
patients have progressed to the “red zone”, CCP may be less effective, as was the case wi th use of CCP 
in SARS -1  -[8]. The study has been amended to include those on high flow nasal oxygenation , as well 
as those on nasal cannula .  In the ACTT -1 study, 25% of participants on HFNC (ordinal group 6) 
progressed to mechanical ventilation or death [22] These individuals are at elevated risk of progression 
to intubation and it is important to understand if CCP can reduce deterioration of  respiratory status .  
 
This study will permit enrollment of pregnant wome n, breastfeeding women and women of childbearing 
potential. CCP should not pose a pregnancy specific risk, other than the known risks associated with 
blood product infusions in general. However, for pregnant or breastfeeding women, additional counseling 
will be provide as to the lack of data for CCP use in COVID -19 infection during pregnancy and lactation 
and that an adverse event that impacts the participant could also affect an unborn child by affecting 
maternal health.  Pregnant women who chose to enroll  will have the pregnancy outcome recorded.  
 
16 
                                     CAPRI Adaptive protocol  Ver 3.0  7/26/2020  
  
 
 
Figure 2. Natural history of COVID -19 infection with a biphasic initial mild disease (green zone) and 
subsequent severe respirato ry failure (red zone) [23]  
 
    Figure 1 : San Francisco COVID Data Tracker: Total COVID acute care beds and subset of ICU beds [1]. 
 

17 
                                     CAPRI Adaptive protocol  Ver 3.0  7/26/2020  
 
 Antibo dy evaluation of CCP units  
To ensure that CCP units have a sufficient quantity of anti -SARS -CoV-2 antibodies, all CCP units will be 
tested for antibodies. The mean plus 4 standard deviations  over antibodies levels from the pre -COVID -19 
era will be used as  the cut -off for CCP units .  This is based on data indicating 100% specificity  when 
evaluating 71 samples collected from febrile patients with upper respiratory symptoms that were either 
SARS -CoV-2 RT -PCR negative or positive for other respiratory viruses using this cutoff (Lynch et al, 
unpublished)  
 Viral load testing  
Serial nasopharyngeal testing will be conducted to evaluate SARS -CoV-2 viral decline in each arm. 
Metagenomic next generation sequencing (mNGS) will be conducted on PCR specimens. mNGS enable s 
simultaneous profiling of host gene expression and viral load, and assessment of the SARS -CoV-2 viral 
genome. This approach will enable broad detection of host  transcriptional biomarkers that may correlate 
with treatment outcomes, and may reveal biologic al mechanisms underpinning CCP antiviral 
activity.   mNGS will additionally provide an opportunity to assess whether SARS -CoV-2 viral load and 
genotype correlate with  clinical  outcomes and treatment response.  
 Adaptive trial design  
This trial is designed as  a randomized controlled trial of CCP versus a control arm of plasma without 
SARS -CoV-2 antibodies. At this time, the antiviral remdesivir (RDV) will be permitted, as has 
demonstrated a 31% faster time to recovery with RDV vs. placebo in preliminary data f rom a randomized 
controlled trial of hospitalization in COVID -19 patients [24]. The preliminary mortality rate of 8% in the 
RDV arm indicates that hospital -based RDV administration alone was not sufficient to mitigate 
morbidity/mortality associated with severe COVID -19 disease. Should the d ata from the ACTT studies or 
other RDV study indicate a substantial reduction in progression to severe hypoxemia in the target 
population of hospitalized hypoxic COVID -19 patients, the sample size will be recalculated with a potential 
increase if necessary .  
Preliminary findings from the open label, randomized RECOVERY study have demonstrated a mortality 
reduction with dexamethasone use compared to standard of care,  29% vs 41.1% respectively, rate ratio 
of 0.6 4 [95% CI 0.0.51 to 0.81 ] [26]. A smaller mortality reduction was reported in hypoxic patients  of 
23.3% vs 26.2%, r ate ratio of 0.82 [ 95% CI 0.07 to 0.94 ] with no data are available on those on lower vs 
higher level of oxygen support. Given the modest benefit in non -ICU patient s, this protocol will exclude 
use of dexamethasone for COVID treatment at the time of enrollm ent. Participants with progressive 
disease who reach the study hypoxemia endpoint can receive dexamethasone, at the discretion of the 
treating provider.  Of note, our institutional practice does not treat all hospitalized patients with 
dexamethasone as sta ndard of care.  
Other investigational  or off label interventions will not be permitted during t he first 15 days  unless the study 
subject meets the primary endpoint of progression to mechanical intubation . Should evidence become 
available during the study to  support the use of anti-COVID -19 therapeutics, including antivirals and/or 
immune modulators that improve clinical outcomes and/or significantly reduce viral load, the study will 
incorporate these therapies into the study design, with a recalculation of t he sample size.  Given the 
18 
                                     CAPRI Adaptive protocol  Ver 3.0  7/26/2020  
 substantial risk for decompensation, hospitalized hypoxic COVID -19 may benefit from CCP in addition to 
other effective treatment, which may further reduce the risk of respiratory decompensation . 
 Collaboration with longitudinal co horts and data pooling effo rts  
Participants will be encouraged to enroll in a longitudinal observational cohort conducted by 
collaborating investigators with aligned specimens collections to facilitate translational evaluations and 
long term follow -up of immunologic and clinical outcomes.  
Data from this protocol will be pooled with other similar studies of CCP in hospitalized hypoxic 
individuals enrolled in randomized controlled trials of CCP vs. control. Data shared will be de -identified 
and contain no protected health information (PHI).  
 Future direction  
This proof -of-concept clinical trial will lay the foundation for a future study that may incorporate 
hyperimmune IgG  and/or monoclonal antibodies , when available,  along with anti -COVID agents (either 
anti-viral and/or anti -inflammatory str ategies) as emerging data are available to support use as standard 
of care.  This initial study will provide much needed infrastructure and preliminary data to support larger , 
multicenter  trials using either convalescent plasma or hyperimmune IgG across th e greater SF Bay Area.     
 
 
19 
                                     CAPRI Adaptive protocol  Ver 3.0  7/26/2020  
 5 INVESTIGATIONAL PLAN :  
5.1 Study objectives  
OBJECTIVES  ENDPOINTS (OUTCOME MEASURES)  
Primary Objective   
Evaluate the efficacy of convalescent fresh 
frozen plasma from blood donors who have 
recovered from Covid -19 containing antibodies 
to SARS -CoV-2 versus control (standard fresh 
frozen plasma) to prevent mechanical intubation  
within 14 days of CPP administra tion in 
hospitalized patients with COVID -19 who are 
within 3 days of hospital admission or 14 days of 
symptom onset.  
. Progression to  mechanical intubation or death  within the 
first 14 days of enrollment. . A secondary endpoint will 
evaluate progression to endpoint within the first 28 days of 
enrollment.   
 
    
Key Secondary Objectives   
To evaluate the clinical efficacy of CCP  relative 
to the control arm in adults hospitalized with 
COVID -19 according to clinical status (8-point 
ordinal scale) at Day 29  
 
 
 
 
 
  Death;  
 Hospitalized, on invasive mechanical ventilat ion or 
ECMO;  
 Hospitalized, on non -invasive ventilation or high flow 
oxygen devices;  
 Hospitalized, requiring supplemental oxygen;  
 Hospitalized, not requiring supplemental oxygen - 
requiring ongoing medical care (COVID -19 related or 
otherwise);  
 Hospitalized, not requiring supplemental oxygen - no 
longer requires ongoing medical care;  
 Not hospitalized, limitation on activities and/or requiring 
home oxygen;  
 Not ho spitalized, no limitations on activities.  
 
20 
                                     CAPRI Adaptive protocol  Ver 3.0  7/26/2020  
 OBJECTIVES  ENDPOINTS (OUTCOME MEASURES)  
Additional Se condary Objectives   
 
To evaluate the clinical efficacy of different 
investigational therapeutics as compared to the 
control arm as assessed by: 
Clinical Severity  Ordinal scale : 
 Time to an improvement of one category 
and two categories from Day 0 (baseline) 
using an ordinal scale.  
 Subject clinical status using ordinal scale at 
Days 2,5,8,15, 29   
 Mean change in the ordinal scale from Day 
1 to Days 2,5,8,15, 29     
 
 
 Clinical outcome assessed using ordinal scale daily 
while hospitalized and on Days 15, 29 and  120  
 Time to clinical recovery ( defined as ordinal score 1 -
3)  
 
 
 
 
National Early Warning Score (NEWS):  
 Time to discharge or to a NEWS of ≤ 2 
and maintained for 24 hours,  whichever 
occurs first.  
 Change from Day 1 to Days 2,5,8,15, 29    
 NEWS assessed daily while hospitalized  
Oxygenation:  
 Oxygenation use up to Day 90 . 
 Incidence and duration of new oxygen use 
during the study.  
 Oxygen requirement on day 1, 2,5,8,15, 29    
 Days of supplemental oxygen (if applicable) up to 
Day 29  
 PaO2/FiO2 ratio or SpO2/FiO2  
 O2 requirement at day 120 
 
Non-invasive ventilation/high flow oxygen:  
 Non-invasive ventilation/high flow oxygen 
use up to Day 29.  
 Incidence and duration of new non -
invasive ventilation or high flow oxygen 
use during the study.   Days of non -invasive ventilation/high flow oxygen (if 
applicable) up to Day 29  
Invasive Mechanical Ventilation / 
extracorporeal membr ane oxygenation 
(ECMO):  
 Ventilator / ECMO use up to Day 29 . 
 Incidence and duration of new mechanical 
ventilation or ECMO use during the study.   
 Days of invasive mechanical ventilation/ECMO (if 
applicable) up to Day 29.  
Hospitalization  
 Duration of hospitalization (days).  
  
 Days of hospitalization as of Day 29 and day 120 
Mortality  
 15-day mortality  
 29-day mortality  
 120-day mortality  
  
 Date and cause of death (if applicable)  
 
To evaluate the safety of CCP as compared 
to the control arm  as assessed by:   
 SAEs  
21 
                                     CAPRI Adaptive protocol  Ver 3.0  7/26/2020  
  Cumu lative incidence of SAEs  through 
Day 29.  
 Cumulative incidence of Grade 3 and 4 
clinical and/or laboratory AEs through Day 
29. 
 Transfusion associated adverse events  
  Grade 3 and 4 AEs  
 Grade 2 or higher AE’s attributed to CCP  
 
 Exploratory Objectives   
To evaluate the virologic efficacy of CCP 
as compared to the control arm as 
assessed by:  
 Percent of subjects with SARS -CoV-2 
detectable in NP/MTN  sample at Days 
1,5,8,15  
 Quantitative SARS -CoV-2 virus in 
NP/MTN  sample at Days 1,2, 5,8,15  
  
 Qualitative and quantitative polymerase chain 
reaction (PCR) for SARS -CoV-2 in NP/MTN  swab on 
Day 1,2,5,8,15  (while hospitalized)  
 
 
  
22 
                                     CAPRI Adaptive protocol  Ver 3.0  7/26/2020  
  
 
5.2 Study Definitions  
 Enrolled : From time consented to participate until designated as  (i) ineligible based on the 
inclusion/exclusion criteria or withdraws, (ii) been discontinued from the study or (iii) completed the study .  
 Randomized : when a randomization number is assigned . 
 Screen Failures : signed informed consent, but then determined to be  ineligible or withdraws before being 
randomized . 
 Discontinued : randomized, but then withdrawn by investigator or subject withdraws consent  
 Completed:  Subjects are considered completed when they are followed through to day 29, had an adverse 
event or death  occurred prior to day 29. Patients will be asked to have day 29 and day 120 study visits as 
well. 
5.3 Study Population  
 Inclusion Criteria for Enrollment:  
1. Patients ≥18 years of age  
2. Hospitalized with COVID -19  
3. Enrolled within 72 hours of hospitalization OR within day 14 from first signs of illness  
4. Pulmonary infiltrates on chest imaging  
5. Oxygenation of <95% on room air  
6. Laboratory confirmed COVID -19  
 
 Exclusion Criteria  
1. Contraindication to transfusion due to inability to tolerate additional fluid, such as due to 
decompensated congestive heart failure  
2. Baseline requirement for oxygen supplementation prior to COVID -19 infection or use of positive 
pressure therapy for sleep disordered breathing  
3. Currently experiencing severe hypoxemic failure, as defined in study endpoints  
4. Prior receipt of plasma products, IVIG, or hyperimmune globulin within past 3 months  
5. Currently enrolled another interventional clinical trial of COVID -19 treatment.   
 
Note: If taking medications with potential anti -COVID activity that do not have data to support efficacy, 
such as IL-6 antagonists , these medications must be stopped prior to enrollment. Receipt of current 
standard of care COVID -19 treatment , including remdesivir is permitted and should be recorded as a 
concomitant medication .  
 
Note: Pregnancy is not exclusionary but will merit additional discussion of risks & benefits  in the context 
of ongoing pregnancy  
 
 
 
 Subject Withdrawal  
 
1. Subjects can terminate study participation and/or withdraw consent at any time without prejudice.  
2. Randomized subjects who withdraw from the study will be replaced  
3. The investigator may withdraw subjects if they are non -compliant with study procedures or if  the 
investigator determines that continued participation in the study would be harmful to the subject or 
the integrity of the study data  
 
23 
                                     CAPRI Adaptive protocol  Ver 3.0  7/26/2020  
 Discontinuation of the study: The study sponsor, FDA and IRB all have the right to terminate this 
study at any tim e 
 
 Treatment  
 
1. Subjects will be randomized in a 1:1 ratio to receive study drug (convalescent  fresh frozen  
plasma) versus standard plasma , one unit of FFP, approximately 250  ml. A single dose of CCP 
will be provided  
2. Study drug: The investigational product is anti -SARS -CoV-2 convalescent fresh frozen plasma , 
ABO compatible with the patient . Convalescent plasma for this trial will be obtained from Vitalant  
(or American Red Cross if necessary .) Donor screening and plasm a collection are not conducted 
as study specific procedures and will be conducted by the collaborating blood bank according to 
their current SOP.   Patients identified as having recovered from COVID -19 will serve as potential 
donors. Potential donors will be screened using an anti -SARS -CoV-2 serologic assay and 
antibody levels will be determined.  Donors will be screened  for standard transfusion -transmitted 
infections (e.g. HIV, HBV, HCV, West Nile Virus, HTLV -I/II, T. cruzi , Zika virus) both with the 
uniform donor history  questionnaire  (DHQ)  and FDA licensed blood donor screening tests  as 
required by FDA . Plasma will be collected using apheresis technology  or via separate from a 
whole blood donation.   
3. Control plasma will be obtained from Vitalant  (or American Red Cross  if necessary) and will be 
either collected prior to 12/ 1/2019 or tested and confirmed to be negative for anti -SARS -CoV-2. 
4. Convalescent plasma will undergo testing to evaluate for anti-SARS -CoV-2 antibodies;  
5. A sample of the convalescent plasma will be stored for future study to investigate total antibody 
quantitation, neutralizing antibody activity, and future evaluation of other correlates of immunity  
and COVID -19 related analyses.   
6. Both treatment and control plasma will be in standard plasma bags, with International Society of 
Blood Transfusion (ISBT) label s. The convalescent plasma will be  additionally  labelled as 
“COVID 19 Convalescent Plasma” and will have a tie tag indicating “New Drug – Limited by Law 
to Investigational Use.”   
7. Study investigators analyzing the data and participants will be blinded to the randomization. It 
may not be feasible to blind nursing staff to the treatment assignment to ensure proper ABO 
checking of the plasma unit at bedside per s tandard transfusion procedures, but every effort will 
be made to preserve blinding of the investigators, participant, and primary team providing care. 
An unblinded research assistant who is not involved in other aspects of the study will randomize 
the part icipant once enrolled. Randomization will be provided to an unblinded provider who is 
not part of the care team who will place the order for the plasma (CCP vs. control plasma) using 
a paper order that will not be part of the electronic medical record.  
 
 Randomization:  
 
1. Subjects enrolled in the study will be randomized using a  web based randomization procedure   
to receive convalescent plasma  versus non-immune plasma  at a 1:1 ratio .  
 
 
 Study drug administration  
 
0. Drug will be administered within 24 hours of randomization  
24 
                                     CAPRI Adaptive protocol  Ver 3.0  7/26/2020  
 1. Infusion rate  500 mL/hour  
2. Pretreatment to minimize transfusion reactions (e.g. acetaminophen,  diphenhydramine) may be 
given at the discretion of the clinical care team.  
3. If an AE develops during infusion, the infusion may be slowed or stoppe d as per investigator’s  
  decision.  
 Most reactions to plasma are relatively minor and the infusion can generally be 
continued.  Infusion site burning and non -allergic systemic effects can generally be 
managed with slowing of the infusion. Infusion can generally be continued in cases of 
itching or hives after pausing the transfusion, administering antihistamines, and 
observing the patient for worsening.   
 Severe allergic reactions such as, bronchospasm and hypotension, generally require  
discontinuation of the infusion.  
 
 Concomitant medications  
 
Concomitant medications will be documented on the Case Report Form (CRF)  up to day 15.   
 Antibiotics  
 Anticoagulation  
 Any COVID -19 related treatment, including RDV  
 Corticosteroids (> 10 mg prednisone equivalent)  
 Blood products  
 
After this time, only medications related to COVID -19 treatment will be documented for days 16-120 
 
 Prohi bited medications  
 
For study day 1 -15, use of medications, including off -label, expanded access, or investigationa l agents,   
with potential anti -COVID -19 activity should not be administered. These include the following : 
 
 Hydroxychloroquine or chloroquine  
 Lopinavir/ritonavir  (unless already prescribed for HIV infection)  
 IL-6 receptor antagonists  
 High dos e corticosteroids initiated for COVID -19 treatment, and not for another 
indication  
 
If there is uncertainty about possible anti -COVID -19 activity, the medication being  used should be 
discussed with the team . This list will be revised as new data to suppor t or refute efficacy become 
available.   
  
Note: Azithromycin administered for treatment of presumed or confirmed infection will be permitted.  
 
After  study  day 15 or in participants who have reached the study endpoint of severe hypoxemia , use of 
additional anti-COVID -19 treatments such as dexamethasone for those with persistent severe COVID -19 
are permitted but should be recorded.   
 
 
25 
                                     CAPRI Adaptive protocol  Ver 3.0  7/26/2020  
  
5.4 Study procedures  
 
Table 1: Schedule of Ev aluations  
Study period  Screen  Enrollment  
 Transfusion 
(within 24 hours 
of randomization ) Follow up  
Day Within 3d 
prior to 
enrollment  1 
(values within 24 
hours prior to  
enrollment)  1 2 5 8 15 29 120 
Visit window     +/-1 day  +/- 
7d +/- 
14d 
Eligibility  
Informed consent  x         
Demographic and 
Medical history  x         
COVID -19 symptom 
screen  x         
SARS -CoV-2 RT -
PCR for eligibility  within 14 
days          
Pregnancy test          
ABO for plasma 
compatibility  x         
Chest imaging 
(CXR or CT scan)  x         
Oxygenation Status  x x        
Study Drug Administration  
Randomization   x        
Drug infusion    x       
Study Procedures           
Vital signs   x xxx1 daily days 2-82 x2   
Oxygenation status   x  daily  2-82 x x x 
26 
                                     CAPRI Adaptive protocol  Ver 3.0  7/26/2020  
 Symptom screen  x x x x x x x x x 
Day Within 3d 
prior to 
enrollment  Enrollment  
(values within 24 
hours prior to  
enrollment)  Plasma  
transfusion  2 5 8 15 29 120 
Visit window     +/-1 day  +/- 
5d +/- 
14d 
Concomitant 
medications   x  x x x x 
(only COVID treatment 
related)   
Assessment with 8 -
point ordinal scale   x  x x x x x x 
Assessment with 
WHO 11 point 
ordinal scale        x x  
Chest imaging 
(CXR or CT scan) 4     x  x   
Laboratory testing  
CBC (with absolute 
lymphocyte count)   x  x2,5 x2,5 x2,5 x2,5 x6 x 
Renal function, liver 
function test   x  x2,5 x2,5 x2,5 x2,5   
PT, PTT, D -dimer, 
hsCRP, ferritin   x  x2 x2 x2 x2 x6 x 
SARS -CoV-2 RT -
PCR (NP/MTN  
swab) 7  x  x x2, 7 x2, 7 x2, 7   
Blood for future 
testing (includes 
SARS -CoV-2 Ab)7   x   x2, 7 x2, 7 x2, 7 x6 x6 
1 Vital  sign testing, immediately prior to infusion, 10 -20 minutes after start of infusion, at completion of infusion and 30 -60 minutes after the end of the infusion , ideally 
bundled with other required clinical care.  
2 If still hospitalized .  
4 Record most rece nt preceding chest imaging, if available and conducted per standard of care  
5 Record lab values if collected as part of standard of care. Will encourage clinical teams to collect but will not be required .  
6 Blood drawn if in -person visit is feasible  
7Prioritize day 1 research blood collection and nasal swab . Collect on day 5, 8, 15 if feasible  
27 
                                     CAPRI Adaptive protocol  Ver 3.0  7/26/2020  
  
STUDY PROCEDURES  
 
1. Study Protocol by Day:  
 
Day -2 to 1:  
A. Screening (must be completed before randomization)  
B. Informed consent (obtained before performing study related activities)  
C. Baseline Evaluation (at screening) (much of the information will be obtained from the medical record)  
1. Demographics: Age, sex, race  
2. Medical history:  
 Timing of exposure to COVID -19 source patient  
 Acute and chron ic medical conditions  that a risk factors for COVID  
 Medications, allergies  
 Any medical condition arising after consent to be recorded as AE.  
3. COVID -19 symptom screen: Fevers, cough, shortness of breath.  
4. History of illness: Onset of symptoms  
5. Vital signs  
6. Oxygenation status : current FiO2 or liters of O2, route of oxygen support, and oxygen saturation or 
Pa02 (if available)  
7. COVID -19 testing (RT -PCR) Per standard of care. Positive test PCR required within 14 days of 
screening  
8. Baseline Basic Lab Testing  
 ABO  Blood typing, CBC  with absolute lymphocyte count , comprehensive metabolic panel , 
inflammatory and coagulation markers (d -dimer, hsCRP, PT/INR, PTT ) 
9. For females of childbearing potent ial,  urine or serum pregnancy test  
 Results from laboratory tests obtained up to 14 days before enrollment may be used for the 
pregnancy test  
 
D. Determination of eligibility  
 Inclusion/exclusion criteria a ge 
 Consent  
 Positive for COVID -19 within past 14 days  
 not already an ICU patient  
 Within 14 days of first sign of illness or within 72 hours of admission  
 
Day 1:  
1. Randomization of eligible subject  
2. Study Plasma Administration :  
 1 unit of plasma will be transfused  within 24 hours of enrollment  
 Time at start and end of infusion will be recorded  
 Vital signs will be measured immediately prior to infusion, 10 -20 minutes after start of infusion, 
at completion of infusion and 30 -60 minutes after the end of the infusion  
4. Assessment of clinical statu s (8-point ordinal scale)  
5. New medical conditions, concomitant medication, AE evaluation  
7. Oxygenation status : current FiO2 or liters of O2, route of oxygen, and oxygen saturation or Pa02 (if available)  
8.  COVID -19 testing (RT -PCR): nasopharyngeal samp les 
10. Stored samples for future studies  (3 EDT tubes and 1 SST ).  This will include s erological testing  for SARS 
CoV-2 antibodies  
 
28 
                                     CAPRI Adaptive protocol  Ver 3.0  7/26/2020  
 Day 2-15  (if remain hospitalized)  
    
1. Vitals signs (day 2 -8)  
3. Assessment of clinical status (8 -point ordinal scale)  (days 2,5,8 ) 
4. New medical conditions,  concomitant medications , AE evaluation  (days 2,5,8 ) 
6. Oxygenation status : current FiO2 or liters of O2, route of oxygen, and oxygen saturation or Pa02 (if available)  
(days 1 -8)  
7. Nasopharyngeal or mid-turbinate nasal swabs , if feasible   (days 2,5,8 ) 
8.  Stored samples for future studies (3 EDT tubes and 1 SST)  (day 5, 8 only)  if feasible.  This testing i ncludes 
SARS -CoV-2 antibody testing  
10. CXR (or CT with increased oxygen requirement): day 5,(record most recent imaging prior to day 5, 
conducted per standard of care)  
Day 15 (phone contact if no longer hospitalized  or if in person visit is not feasible ) 
 
1. COVID -19 symptom screen (fevers, cough, shortness of breath)  
2.  Assessment of clinical status ( 8-point ordinal scale)  & WHO 11 point scale [27] (added to facilitate data 
analysis across data sets)   
3.  New medical conditions, AE evaluation , concomitant medications   
4. Oxygenation status : current FiO2 or liters of O2, route of oxygen, and oxygen saturation or Pa02 (if available)  
5.  CBC, comprehensive metabolic panel, inflammatory markers  (if seen in person)  
6.  Serological testing: anti -SARS CoV -2 antibody level s if hospitalized  
7.  Nasopharyngeal or mid -turbinate nasal swabs with OP swab if possible (if seen in person)  
8.  CXR (or CT with increased oxygen requirement): day 15,(record most recent imaging prior to day 15, 
conducted per standard of care)  
9.  Stored samples for future studies (3 EDTA, 1 SST)   (if seen in person)  
 
Day 2 9: (in person visit if feasible , phone contact if not )    
 
1. COVID -19 symptom screen (fevers, cough, shortness of breath)  
2. Assessment of clinical status (8 -point ordinal scale)  & WHO 11 point scale [27] (added to facilitate data 
analysis across data sets)   
3. Oxygen ation status : current FiO2 or liters of O2, route of oxygen, and oxygen saturation or Pa02 (if 
available)  
4. New medical conditions, AE evaluation , concomitant medications (only recorded if treatment given for 
COVID -19 after day 15)  
5. CBC, inflammatory markers (if seen in person)  
6. Blood for stored testing, if feasible (3 EDTA, 1 SST) This will include s erological testing  for SARS CoV -2 
antibodies  
 
 
Day 120 In-person (if feasible)  
 
1. COVID -19 symptom screen (fevers, cough, shortness of breath)  
2. Assessment of clinical status ( 8-point ordinal scale)   
3. New medical conditions, AE evaluation  
4. Serological testing: anti -SARS CoV -2 antibody level s 
5. Blood for stored testing, if feasible (3 EDTA, 1 SST) . This will include s erological testing  for SARS CoV -2 
antibodies  
 
 
29 
                                     CAPRI Adaptive protocol  Ver 3.0  7/26/2020  
  
 
 
 
8 point  WHO  ordinal Scale of clinical status [28] 
 
 
 
 
 
 
 
 
 
 
 
 
 

30 
                                     CAPRI Adaptive protocol  Ver 3.0  7/26/2020  
  
 
11 point WHO ordinal Scale [27] 
 
 

31 
                                     CAPRI Adaptive protocol  Ver 3.0  7/26/2020  
 6 STATISTICAL PLAN  
 
6.1 Sample Size and Power Considerations  
All power calculations were performed using Stata “power” package  assuming a two -tailed α=0.05. The 
planned sample size for the trial is 50 subjects, randomized in a 1:1 ratio to anti -SARS -CoV-2 convalescent 
plasma versus control plasma.  The primary analysis will compare the combined endpoint of mechanical 
ventilation or death  in the anti -SARS -CoV-2 convalescent plasma and control groups.  
We base our sample size projection on the ACTT -1 data [22]They  reported the progression within 15 days 
separately for COVID -19 hospitalized requiring supplemental oxygen and those requiring high flow oxygen 
or non -invasive ventilation. The proportion progress ing were 20% and 34%, respectively in the standard of 
care group and 8% and 25% in the remdesivir group progression. For our assumption we assume a 32% 
progression rate on the standard of care (no  convalescent plasma)  In the absence of treatment with 
convalescent plasma, we anticipate that between 10 to 30% will experience the primary outcome of 
mechanical ventilation or death .   Using the Fisher exact test: we will reject the null hypothesis under the 
data scenario in the Table below.  
.   
Rejection Regio n for the Fisher Exact Test  
No. Mechanical ventilation/Death  (%) Control arm (%)  Active arm (%)  
 
5/25 (20%)  0/25 (0%)  
 
6/25 (24%)  <= 1/25 (4%)  
 
7/25 (28%)  <= 1/25 (4%)  
 
8/25 (32%)  <= 1/25 (4%)  
 
9/25 (36%)  <= 2/25 (8%)  
 
10/25 (40%)  <= 3/25 (12%)  
 
We will use an 8 -point ordinal scale to assess clinical status , based on WHO clinical trial guidance . We 
assume the same distribution of outcomes for the control arm (i.e., in the absence of treatment with 
32 
                                     CAPRI Adaptive protocol  Ver 3.0  7/26/2020  
 convalescent plasma) as in ACTT, as tabulated below.   Assuming 25 participants are treated with 
convalescent plasma and 25 participants are untreated, we would have 80% power  to detect a difference 
between treatment arms as follows:  
Category  Control arm (%)  Active arm (%)  
Death  12%  0 
Hospitalized, on invasive mechanical 
ventilation plus additional organ support 
(pressors, RRT, ECMO)  0 0 
Hospitalized, intubated and mechanical 
ventilation  20.0%  0 
Hospitalized, on non -invasive ventilation or 
high flow oxygen devices;  12% 8% 
Hospitaliz ed, requiring supplemental 
oxygen fy mask or nasal prong  0 20%  
Hospitalized, not requiring supplemental 
oxygen – requiring ongoing medical care 
(COVID -19 related or otherwise);  24% 12%  
Not hospitalized, limitation on activities  16% 28%  
Not hospitalized, no limitations on 
activities.  16% 32%  
 
 
 
6.2 Statistical Analysis  
 
 Primary endpoint  
Our primary hypothesis is that by providing anti -SARS -CoV-2 plasma, the rate of progression to 
mechanical ventilation or death  will be decreased as compared to the rate in in the group receiving control 
plasma. We will apply a Fisher exact  test to compare the combined endpoint of mechanical 
ventilation/death respiratory failure  rates between the two groups  occurring by day 15.  2 9. All analyses 
33 
                                     CAPRI Adaptive protocol  Ver 3.0  7/26/2020  
 will be conducted with a modified intention -to-treat approach, which excludes randomized subjects who 
do not initiate an infusion of the study plasma. As secondary analysis, we will also analyze the reduced 
oxygenation rate, requirement for  supplemental oxygen rate, length of hospitalization, time to recovery 
(ordinal score 1 -3) and mechanical ventilation rate, respectively , as well as occurrence of the primary 
endpoint by day 29  Statistical inference will be based on a two -sided Type 1 err or rate of 0.05 and 95% 
confidence intervals.  
Participants who are intubated for reasons other than hypercarbia/hypoxia, such as for a procedure or 
airway obstruction, will have ventilation settings evaluated to determine if need for ventilation due to 
hypoxia is meet. This will be determined by >12 hours of requirement for a mandatory mode of ventilation 
(volume control or pressure control) or Fi02 of > 40%. External adjudication of intubation for non -
hypoxic/hypercarbic indication will be conducted.  
 
 Secondary  endpoint (clinical status) : 
 
We will evaluate the clinical efficacy of CCP relative to the control arm in adults hospitalized with COVID -
19 according to clinical status (8 -point  WHO  ordinal scale) using a proportional odds model.  Because 
clinical s tatus is evaluated on multiple days, we will use a generalized estimating equations (GEE) 
approach to account for repeated measures within each patient. Changes in ordinal scale at each 
timepoint will be summarized by proportions.  
 Other secondary endpoints : 
Differences in time -to-event endpoints (e.g., death, hospital discharge) will be summarized by treatment 
arm using Kaplan -Meier curves and 95% confidence bounds.   Duration of events (e.g., days of 
hospitalization, supplemental oxygen, ventilation) will b e summarized by treatment arm by median days 
with quartiles.  Binary data (e.g., incidence of new oxygen use) will be summarized by treatment arm as 
percentages with 95% confidence intervals.  Categorical data (e.g., 29-day mortality, ordinal scale by day)  
will be summarized by treatment arm as proportions by category and using odds ratios with 95% 
confidence intervals.  
 
 Analysis of AE data  
Analysis of AE data will primarily be descriptive based on DAIDS toxicity table coding of events. Rates of 
AE will be compared between randomized arms using Fisher’s Exact Test.  
 
 Analysis of the anti -SARS -CoV-2 levels and inflammatory markers.  
Analysis of antibody level s will primarily be descriptive, comparing the geometric mean antibody levels  at 
days 1,2,5,8 ,15, 29, and 120 between the randomized arms. Furthermore, it is of interest to describe the 
entire distributions of anti -SARS -CoV-2 antibody level s by randomized arms and contrast these 
distributions. Therefore, we will use quantile regression in order to describe whether there is a shift or 
change in the titer distribution between randomized arms. Given that repeated measures of antibody levels  
will be obtained, we will account for the correlation in measures within individuals using a cluster bootstrap 
34 
                                     CAPRI Adaptive protocol  Ver 3.0  7/26/2020  
 in order to  properly estimate the p -value and 95% confidence intervals.  Similar analysis will also be applied 
to lymphocyte counts on days 1,2,5,8 ,15, 29 hematological measurements (D -dimer , ferritin , hsCRP ) on 
days 1,2,5,8 ,15, 29, 29, and other lab measures showing right-skewed distributions . Exploratory analyses 
of antibody isotypes,neutralizing antibody activity, antibody affinity, glycosylation and T -cell responses will 
be conducted to compare between arms and over time.  
 
 Analysis the rates, levels and duration of SARS -CoV-2 RNA in NP/MTN  swabs  
This secondary analysis will be primarily descriptive. The proportion positive at days 1,2,5,8, and 15  and 
whether individuals lose positivity status at a subsequent visit among tho se who were initially positive will 
be examined. To determine the proportion that are positive at each visit, we will do a pooled 
complementary log -log model in order to describe the cumulative incidence of SARS -CoV-2 positivity over 
time. The pooled compl ementary log -log model is a discrete time -to-event -analysis that estimates the log 
hazard rate at each discrete time point. Similar to the analysis of anti -SARS -CoV-2 antibody levels , the 
goal of this secondary aim is to describe the distribution of SARS -CoV-2 RNA between randomized arms. 
Therefore, we will use the same approach as that for the anti -SARS -CoV-2 antibody levels . Because the 
exact day that an individual becomes negative is not known, a minimum and maximum amount of positive 
time will be used t o describe the positive duration of each individual. If the sample is adequate, we will 
describe the duration of positivity using a non -parametric approach for time -to-event analysis.  
 
 Analysis of ICU rate, in-hospital mortality and 29 day mortality  
The goal is to compare ICU rate and mortality between randomized arms. We will use the same approach 
as above for the primary outcome ( respiratory failure  rate).  
6.3 Adaptive trial design  
During the conduct of this trial, new data may emerge to support the cl inical and/or antiviral efficacy of 
an anti -COVID therapy such that this therapy becomes a standard of care. Should this occur, the 
sample size will be recalculated taking into account the anticipated effect size of the new therapy and 
any data to inform t he anticipated additive or synergistic effect of the therapy when coadministered with 
CCP. This therapy will be incorporated into the study as soon as possible as the background standard of 
care, with an expanded sample size as appropriate.  
 
35 
                                     CAPRI Adaptive protocol  Ver 3.0  7/26/2020  
 7 HUMAN SUBJECT S PROTECTIONS  
7.1  Risks and Benefits  
 
Potential Benefits of Treatment : The potential benefits of antiviral treatment with anti -SARS CoV -2 plasma 
in patients with COVID -19 and respiratory symptoms consistent at high risk for respiratory 
decompensation  are not known. We hypothesize  that treatment will decrease the risk of disease 
progression requiring  supplemental oxygen, ICU admission and aggressive respiratory support including 
possible mechanical ventilation (and other ICU support).  
Potential Benefi ts of Clinical monitoring and Virologic Testing : Monitoring and testing are required to 
assess the effect of convalescent plasma on the course of C OVID -19 respiratory disease.     
 Potential risks  
 
1. Risks of Plasma: Fever, chills, rash, headache, serious allergic reactions, TRALI, TACO, transmission  
    of infectious agents  
2. Risks of Phlebotomy: local discomfort, bruising, hematoma, bleeding, fainting,  
3. Total blood draws will not exceed 500 mL  
4. Risks of oropharyngeal and throat swab: local discomfort, vomiting , coughing  
 
Alternatives : The alternative to participation in this study is routine care.  
 
  Safety measures  
 
1. Safety Evaluations will assess for clinical and laboratory indices of reactions to high antibody level  
anti-SARS -CoV-2 plasma and determine if they are  higher, lower or the same as standard plasma  
2. Clinical evaluations: Vital signs and symptom screen on days 1-8, 15 and symptom screens on days 
29, and 120. 
3. Laboratory evaluations to include chest radiography ( chest x-rays and /or chest CT  and/or ultrasound ) 
Safety laboratory tests (ABO typing, pregnancy testing, CBC, CRP, and comprehensive metabolic 
panel) will be performed at the local CLIA -certified clinical laboratory on days 1-8 and 15 as specified 
by above plan.  
 
7.2 Definitions  
 
1. Adverse E vent (AE) : Any untoward medical occurrence in a clinical investigation subject who has 
received a study intervention and that does not necessarily have to have a causal relationship with the 
study product. An AE can, therefore, be any unfavorable and unintended sign (including an abnormal 
laboratory finding, for example), symptom, or disease temporally associated with the use of the study 
product, wh ether or not considered related to the study product.  
 
2. Serious Adverse Event (SAE): Any adverse event that results in any of the following outcomes:  
1. Death  
2. Life-threatening (immediate risk of death)  
3. Prolongation of existing hospitalization  
4. Persistent or significant disability or incapacity  
36 
                                     CAPRI Adaptive protocol  Ver 3.0  7/26/2020  
 5. Important medical events that may not result in death, be life threatening, or require intervention or 
escalation of care may be considered a serious adverse event when, based upon appropriate medical 
judgment, they may jeopardize the subject and may require medical or surgical intervention to prevent 
one of the outcomes listed in this definition. Examples of such medical events include allergic 
bronchospasm requiring intensive treatment in an emergency room or at home, blood dyscrasias or 
convulsions that do not result in inpatient hospitalization.  
 
3. Unexpected Adverse Event (UAE):  An adverse reaction, the nature or severity of which is not 
consistent with the investigator’s brochure.  
 
4. Serious and U nexpected Suspected Adverse Reaction (SUSAR) : An adverse reaction, the nature 
of which is not consistent with the investigator’s brochure with severity as defined by SAE above.  
 
5. Unanticipated Problem (UP) : Unanticipated Problem that is not an Adverse Event (e.g. breaches of 
confidentiality, accidental destruction of study records, or unaccounted -for study drug).  
 
6. Protocol Deviation:  Deviation from the IRB -approved study procedures. Designated serious and non -
serious  
 
7. Serious Protocol Deviation:  Protocol deviation that is also an SAE and/or compromises the safety, 
welfare or rights of subjects or others  
 
7.3  Safety Reporting  Requirements  
 
 Reporting Interval  
 
All grade 3 and 4 AE’s, grade 2 AE attributed to study product  and SAEs will be documented from the first 
administration of study product . These  AEs and SAEs will be followed until resolution even if AEs extend 
beyond the study -reporting period. Resolution of an adverse event is defined as the return to pre -treatment 
status or stabilization of the condition with the expectation that it will remain chronic. At any time after 
completion of the study, if the  investigator becomes aware of a SAE that is suspected to be  related to 
study product .  
 
 Investigator’s Assessment of Adverse Events  
 
The determination of seriousness, severity, and causality will be made by an on -site investigator who is 
qualified (licen sed) to diagnose adverse event information, provide a medical evaluation of adverse 
events, and classify adverse events based upon medical judgment. This includes but is not limited to 
physicians, physician assistants, and nurse practitioners.  
 
Laboratory abnormalities will be reported as AEs if there is a 2 standard deviation  increase above 
baseline.  
 
 Assessment  of Seriousness  
 
1. Event seriousness will be determined according to the protocol definition of an SAE  
2. Assessment  of Severity  
 
Event severity  will be graded using the DAIDS toxicity table  
https://rsc.niaid.nih.gov/sites/default/files/daidsgradingcorrectedv21.pdf  
 
37 
                                     CAPRI Adaptive protocol  Ver 3.0  7/26/2020  
 
 Assessment  of Association  
 
1. The association assessment categories that will be used for this study are:  
 Associated – The event is temporally related to the administration of the study product and no 
other etiology explains the ev ent. 
 Not Associated – The event is temporally independent o f the study product and/or the event 
appears to be explained by another etiology.  
 
2. The investigator must provide an assessment of association or relationship of AEs to the study 
product based on:  
 Temporal relationship of the event to the administration  of study product  
 Whether an alternative etiology has been identified  
 Biological plausibility  
 Existing therapy and/or concomitant medications.  
7.4  Safety Oversight  
 
 Monitoring Plan  
1.  AE requiring reporting as per above and SA E will be reviewed by protocol team weekly , or more  often  
if needed.  
 
 
2.  A  Safety Monitoring Committee (SMC)  composed of independent experts without conflict of interests will 
be established . The SMC will review the study before initiation , after enrollment of patient 5 and  patient 15, 
and monthly thereafter until enrollment completed. The SMC  will review study data , including unblinded data, 
to evaluate the safety, efficacy, study progress, and conduct of the study . 
 
7.5 Study compliance with cl inical trial requirements   
1. Study will be conducted in accordance with GCP and ICH. Specifically, regular QC will be conducted 
to document the following:  
a. There is documentation of the informed consent process and signed informed consent 
documents for e ach participan t 
b. There is compliance with recording requirements for data points  
c. All SAEs are reported as required  
d. Individual participant  study records and source documents align  
e. Investigators are in compliance with the protocol  
d. Regulatory requirements as per Office for Human Research Protections  (OHRP), FDA, and  
  applicable guidelines (ICH -GCP) are being followed.  
 
38 
                                     CAPRI Adaptive protocol  Ver 3.0  7/26/2020  
 8 STUDY MODIFICATION  
8.1 Halting Criteria for the Stud y 
 
The study enrollment and dosing will be stopped and an ad hoc review by the SMC will be performed if 
any of the specific following events occur  or, if in the judgment of the study physician, participan t safety is 
at risk of being compromised:  
 
 1. Death within one hour of plasma infusion  
 
 2. Occurrence of a life -threatening allergic/hypersensitivity reaction (anaphylaxis), manifested by 
bronchospasm with or without urticaria or angioedema requiring hemodynamic support with pressor 
medications or mechanical ventilation, TRALI, TACO . 
 
3.  One participan t with an SAE associated with study product.  
 
4. Two participants  with a Grade  3 or higher lab toxicity for the same parameter associated with 
study product.  (Grading will be assessed using DAIDS Toxicity Table 
https://rsc.niaid.nih.gov/sites/default/files/daidsgradingcorrectedv21.pdf ) 
 
5. An overall pattern of symptomatic, clinical, or laboratory events that the SMC  consider s 
associated with study product and that may appear minor in terms o f individual events but that 
collectively may represent a serious potential concern for safety.  
 
6. Any other event(s) which is considered to be a serious adverse event in the good clinical 
judgment of the responsible physician. This will be appropriately documented.  
8.2 Halting Criteria/Rules for Subject Infusion : 
 Infusion of study drug will be halted if any of the following manifestations of anaphylaxis develop and 
will not be restarted:  
 Skin or mucous membrane manifestations: hives, pruritus, flushing, swollen lips, tongue or uvula  
 Respiratory compromise: dyspnea, wheezing, stridor, hypoxemia  
 A decrease in systolic blood pressure to < 90 mmHg or >30% decrease from baseline or a 
diastolic drop of >30% from baseline.  
 Tachycardia with an increase in resting  heart rate to > 130  beats per minute ; or bradycardia <40 
that is associated with dizziness, nausea or feeling faint.  
 Any other symptom or sign which in the good clinical judgment of the study clinician or supervising 
physician warrants halting the infusio n. For example, the rapid onset of gastrointestinal symptoms, 
such as nausea, vomiting, diarrhea, and cramps, for instance, may be manifestations of anaphylaxis 
and may warrant an immediate halt prior to meeting full SAE criteria  
 
39 
                                     CAPRI Adaptive protocol  Ver 3.0  7/26/2020  
 9 ETHICS/PROTECTION OF  HUMA N SUBJECTS  
 
9.1 Ethical Standard  
UCSF  is committed to the integrity and quality of the clinical studies it coordinates and implements. UCSF 
will ensure that the legal and ethical obligations associated with the conduct of clinical research involving 
human subj ects are met. The information provided in this section relates to all UCSF sites participating in 
this research study  
This assurance commits a research facility to conduct all human subjects’ research in accordance with 
the ethical principles in The Belmon t Report and any other ethical standards recognized by OHRP. Finally, 
per OHRP regulations, the research facility will ensure that the mandatory renewal of this assurance 
occurs at the times specified in the regulations.  
 
9.2 Institutional Review Board  
 
This s tudy will be reviewed by Advarra, under an intent to relay agreement via the UCSF IRB   
9.3 Informed Consent Process  
The informed consent process will be initiated before a volunteer agrees to participate in the study and 
should continue throughout the individual’s study participation. Informed consent will be obtained in 
accordance with site SOP for COVID consenting and  in compliance with current FDA guidance for 
consenting in setting of COVID pandemic https://www.fda.gov/media/136238/download . A copy of the 
signed informed consent document will be given to the su bject for their records. The consent will explain 
that subjects may withdraw consent at any time throughout the course of the trial. Extensive explanation 
and discussion of risks and possible benefits of this investigation will be provided to the subjects in 
understandable language. Adequate time will be provided to ensure that the subject has time to consider 
and discuss participation in the protocol. The consent will describe in detail the study 
interventions/products/procedures and risks/benefits associa ted with participation in the study. The rights 
and welfare of the subjects will be protected by emphasizing that their access to and the quality of medical 
care will not be adversely affected if they decline to participate in this study.  
9.4  Subject Confidentiality  
Subject confidentiality is strictly held in trust by the participating investigators, their staff, and the sponsors 
and their agents. No information concerning the study or the data will be released to any unauthorized 
third party without p rior written approval of the sponsor. The results of the research study may be 
published, but subjects’ names or identifiers will not be revealed. Records will remain confidential. To 
maintain confidentiality, the PI will be responsible for keeping records  in a locked area and results of tests 
coded to prevent association with subjects’ names. Data entered into computerized files will be accessible 
40 
                                     CAPRI Adaptive protocol  Ver 3.0  7/26/2020  
 only by authorized personnel directly involved with the study and will be coded. Subjects’ records will be 
available to the FDA,  Vitalant, investigators at the site involved with the study, and the IRB.  
9.5 Future Use of Stored Specimens  
Subjects will be asked for consent to use their samples for future testing before the sample is obtained. 
The confidentiality of the  subject will be maintained. The re will be no plans to re -contact them for consent 
or to inform them of results. The risk of collection of the sample will be the small risk of bruising or fainting 
associated with phlebotomy however these samples will be ta ken at the same time as other protocol 
required samples.  No human genetic testing will be performed on the samples.  3 EDTA tubes and 1 SST 
tube will be collected (see Schedule of Events).. These samples will be used to answer questions that 
may arise whil e the study is underway or after it is completed. If for instance, there were unanticipated 
AEs, serum could be used to run tests that might help determine the reason for the AEs. Cytokines could 
be measured, for example.  
Samples would not be shared with i nvestigators other than investigators included in this protocol unless 
outside investigators had relevant assays or expertise not available to the study investigators. The 
specimens would remain linked and at UCSF or with study collaborator Vitalant  for 5 years. Any use of 
these specimens not specified in the current protocol will be reviewed by the  Einstein  IRB. 
9.6 Data management and monitoring  
 Source Documents  
 
The primary source documents for this study will be the subjects’ medical records. If the investi gators 
maintain separate research records, both the medical record and the research records will be considered 
the source documents for the purposes of auditing the study. The investigator will retain a copy of source 
documents. The investigator will permi t monitoring and auditing of these data, and will allow the IRB and 
regulatory authorities access to the original source documents. The investigator is responsible for ensuring 
that the data collected are complete, accurate, and recorded in a timely manner . Source documentation 
(the point of initial recording of information) should support the data collected and entered in to the study 
database and must be signed and dated by the person recording and/or reviewing the data. All data 
submitted should be revie wed by the site investigator and signed as required with written or electronic 
signature, as appropriate. Data entered into the study database will be collected directly from subjects 
during study visits or will be abstracted from subjects’ medical records . The subjects’ medical records 
must record their participation in the clinical trial and what medications (with doses and frequency) or other 
medical interventions or treatments were administered, as well as any AEs experienced during the trial.  
 
 Data Management Plan  
Study data will be collected at the study site(s) and entered into the study database. Data entry is to be 
completed on an ongoing basis during the study.  
 
41 
                                     CAPRI Adaptive protocol  Ver 3.0  7/26/2020  
 
 Data Capture Methods  
Clinical data will be entered into a 21 CFR 11 -compliant Intern et Data Entry System (IDES). The data 
system includes password protection and internal quality checks to identify data that appear inconsistent, 
incomplete, or inaccurate.  
 
 Study Record Retention  
 
The PI is responsible for retaining all essential documents  listed in the ICH GCP Guidelines. The FDA 
requires study records to be retained for up to 2 years after marketing approval or disapproval (21 CFR 
312.62), or until at least 2 years have elapsed since the formal discontinuation of clinical development of 
the investigational agent for a specific indication. These records are also to be maintained in compliance 
with IRB/IEC, state, and federal medical records retention requirements, whichever is longest. All stored 
records are to be kept confidential to the e xtent provided by federal, state, and local law.  
No study document should be destroyed. Should the investigator wish to assign the study records to 
another party and/or move them to another location, the site investigator must provide written notification  
of such intent to sponsor with the name of the person who will accept responsibility for the transferred 
records and/or their new location. The sponsor must be notified in writing and written permission must be 
received by the site prior to destruction or  relocation of research records.  
  
42 
                                     CAPRI Adaptive protocol  Ver 3.0  7/26/2020  
  
 
REFERENCES  
 
1. SFDPH. San Francisco COVID -19 Data Tracker . 2020; Available from: https://data.sfgov.org/COVID -19/COV ID-19-
Hospitalizations/nxjg -bhem . 
2. Casadevall, A. and L.A. Pirofski, The convalescent sera option for containing COVID -19. J Clin Invest, 2020.  
3. Casadevall, A. and M.D. Scharff, Serum therapy revisited: animal models of infection and development of passive 
antibody therapy.  Antimicrob. Agents Chemotherap, 1994. 38(8): p. 1695 -1702.  
4. Casadevall, A., E. Dadachova, and L.A. Pirofski, Passive antibody therapy for infectious diseases.  Nat. Rev. 
Microbiol, 2004. 2(9): p. 695 -703.  
5. Zhang, J.S., et al., A serological survey on neutralizing antibody titer of SARS convalescent sera.  J Med Virol, 2005. 
77(2): p. 147 -50. 
6. Sahr, F., et al., Evaluation of convalescent whole blood for treating Ebola Virus Disease in Freetown, Sierra Leone.  
J Infect, 2017. 74(3): p. 302 -309.  
7. Casadevall, A. and L. Pirofski, The damage -response framework of microbial pathogenesis.  Nat. Rev. Microbiol, 
2003. 1: p. 17 -24. 
8. Cheng, Y., et al., Use of convalescent plasma therapy in SARS patients in Hong Kong.  Eur J Clin Microbiol Infect 
Dis, 2005. 24(1): p. 44 -6. 
9. Yeh, K.M., et al., Experience of using convalescent plasma for severe acute respiratory syndrome among 
healthcare workers in a Taiwan hospital.  J Antimicrob Chemother, 2005. 56(5): p. 919 -22. 
10. Ko, J.H., et al., Chall enges of convalescent plasma infusion therapy in Middle East respiratory coronavirus 
infection: a single centre experience.  Antivir Ther, 2018. 23(7): p. 617 -622.  
11. Arabi, Y.M., et al., Feasibility of Using Convalescent Plasma Immunotherapy for MERS -CoV Infection, Saudi 
Arabia.  Emerg Infect Dis, 2016. 22(9): p. 1554 -61. 
12. van Erp, E.A., et al., Fc-Mediated Antibody Effector Functions During Respiratory Syncytial Virus Infection and 
Disease.  Front Immunol, 2019. 10: p. 548.  
13. Gunn, B.M., et al., A Role  for Fc Function in Therapeutic Monoclonal Antibody -Mediated Protection against Ebola 
Virus.  Cell Host Microbe, 2018. 24(2): p. 221 -233 e5.  
14. Duan, K., et al., Effectiveness of convalescent plasma therapy in severe COVID -19 patients.  Proceedings of the 
National Academy of Sciences, 2020: p. 202004168.  
15. Shen, C., et al., Treatment of 5 Critically Ill Patients With COVID -19 With Convalescent Plasma.  JAMA, 2020.  
16. Wan, Y., et al., Molecular Mechanism for Antibody -Dependent Enhancement of Coronavirus Ent ry. J Virol, 2020. 
94(5). 
17. Mair -Jenkins, J., et al., The effectiveness of convalescent plasma and hyperimmune immunoglobulin for the 
treatment of severe acute respiratory infections of viral etiology: a systematic review and exploratory meta -
analysis.  J Infect Dis, 2015. 211(1): p. 80 -90. 
18. Crowe, J.E., Jr., C.Y. Firestone, and B.R. Murphy, Passively acquired antibodies suppress humoral but not cell -
mediated immunity in mice immunized with live attenuated respiratory syncytial virus vaccines.  J Immunol, 2001. 
167(7): p. 3910 -8. 
19. FDA. Investigational COVID -19 Convalescent Plasma: Guidance for Industry . 2020; Available from: 
https://www.fda.gov/media/136798/download . 
20. Joyner, M. and  e. al, Early Safety Indicators of COVID -19 Convalescent Plasma in 5,000 Patients.  MedRxiv, 2020.  
21. Roback, J.D. and J. Guarner, Convalescent Plasma to Treat COVID -19: Possibilities and Challenges.  JAMA, 2020.  
22. Beigel, J.H., K.M. Tomashek, and L.E. Do dd, Remdesivir for the Treatment of Covid -19 - Preliminary Report. Reply.  
N Engl J Med, 2020. 383. 
23. Bouadma, L., et al., Severe SARS -CoV-2 infections: practical considerations and management strategy for 
intensivists.  Intensive Care Med, 2020. 46(4): p.  579-582.  
43 
                                     CAPRI Adaptive protocol  Ver 3.0  7/26/2020  
 24. NIAID. NIH Clinical Trial Shows Remdesivir Accelerates Recovery from Advanced COVID -19. 2020  4/29/2020]; 
Available from: niaid.nih.gov/news -events/nih -clinical -trial-shows -remdesivir -accelerates -recovery -advanced -
covid -19. 
25. Horby, P., et al., Effect of Dexamethasone in Hospitalized Patients with COVID -19: Preliminary Report.  medRxiv, 
2020: p. 2020.06.22.20137273.  
26. Group, R.C., et al., Dexamethasone in Hospitalized Patients with Covid -19 - Preliminary Report.  N Engl J Med, 
2020.  
27. Characterisation, W.H.O.W.G.o.t.C. and C. -i. Management of, A minimal common outcome measure set for 
COVID -19 clinical research.  Lancet Infect Dis, 2020.  
28. WHO. Novel coronavirus, COVID -19 Therapeutic Trial Synopsis. World Health Organization R&D Bluepri nt. 
2/18/2020; Available from: https://www.who.int/blueprint/priority -diseases/key -action/COVID -
19_Treatm ent_Trial_Design_Master_Protocol_synopsis_Final_18022020.pdf . 
 